Skip to search formSkip to main contentSkip to account menu

orteronel

Known as: Androgen Synthesis Inhibitor TAK-700, 6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide, 6-((7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthamide 
An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

ImidazolesNaphthalenes
NCIt Antineoplastic Agent Terminology

Narrower (1)

TAK-700

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Непрямое сравнение эффективности и безопасности энзалутамида, абиратерона и кабазитаксела при лечении кастрационно-резистентного рака предстательной железы, прогрессирующего на фоне применения доцетаксела
Background. Castration-resistant prostate cancer (CRPC) is wide-spread severe disease in many regions of the world. Enzalutamide… 
2016
2016
Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis
Background: The frequency of AR expression varies in the different breast cancer subtypes with 88%, 59%, and 32% expression… 
2015
2015
Effect of CYP17A1 Inhibitors Orteronel and Galeterone on Adrenal Androgen Biosynthesis
2015
2015
Prostate cancer: The end of the road for orteronel
2014
2014
Orteronel Delays Disease Progression in Advanced Prostate Cancer
The investigational therapy orteronel delayed disease progression in patients with metastatic castration-resistant prostate…